Results 51 to 60 of about 74,377 (332)

CYP4X1/sEH‐Dependent Endocannabinoid Metabolism Drives Fibroblast‐Mediated Immunosuppression to Limit Immunotherapy in Colon Cancer

Advanced Science, EarlyView.
A proposed mechanism to explain the role of CYP4X1/sEH‐14,15‐EET‐EA system in colon cancer immune escape. 14,15‐EET‐EA, 14,15‐epoxyeicosatrienoic acid‐ethanolamide; sEH, soluble epoxide hydrolase; CYP4X1, cytochrome P450 4X1; GPR119, G‐protein coupled receptor 119; EGFR, epidermal growth factor receptor; Gs, Gαs subunit; cAMP, cyclic adenosine ...
Min Mo, Xuewei Chen, Yanzhuo Liu, Chenlong Wang, Xuehan Chen, Nan Zhang, Nan He, Ying Li, Jingyi Wang, Honglei Chen, Jing Yang   +10 more
wiley   +1 more source

The development and therapeutic potential of classical and next-generation cannabinoid ligands

Pharmacological Research
The endogenous cannabinoid system (ECS) is a complex network that plays a crucial role in various physiological processes, and its modulation through cannabinoid ligands has garnered significant interest in pharmacological research. Cannabinoid receptors,
Verónica Muñoz-Canales, Bellinda Benhamú, Mar Martín-Fontecha, Henar Vázquez-Villa, Silvia Ortega-Gutiérrez   +4 more
doaj   +1 more source

Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB2 receptor

Pharmacology Research & Perspectives, 2023
The rapid structural evolution and emergence of novel synthetic cannabinoid receptor agonists (SCRAs) in the recreational market remains a key public health concern.
Monica Patel, Natasha L. Grimsey, Samuel D. Banister, David B. Finlay, Michelle Glass   +4 more
doaj   +1 more source

Cognitive impairment induced by delta9-tetrahydrocannabinol occurs through heteromers between cannabinoid CB1 and serotonin 5-HT2A receptors [PDF]

, 2015
Delta-9-tetrahydrocannabinol (THC), the main psychoactive compound of marijuana, induces numerous undesirable effects, including memory impairments, anxiety, and dependence.
A Busquets-Garcia, A Castañé, A Kern, A Manglik, A Pazos, A Pertovaara, A Zimmer, AC Magalhaes, AJ Venkatakrishnan, AL Bodor, Antoni Pastor, AR Best, Arnau Cordomí, BB Gorzalka, C Bombardi, C Castellano, C Ferrada, C Sanchis-Segura, Carmen Lluís, CP Vandermaelen, E Aso, E Fiorica-Howells, E Moreno, E Moreno, E Moreno, E Palazzo, E Puighermanal, E Puighermanal, E Valjent, Enric I. Canela, Eric J. Nestler, Estefanía Moreno, ET Weber, F Berrendero, F Rodríguez de Fonseca, F Simonin, F Steindel, FA Moreira, G Di Chiara, G Mengod, G Paxinos, G Porras, G Soria, Gemma Navarro, GM Thomas, HY Meltzer, J De Almeida, J González-Maeso, J González-Maeso, JC Parrish, JF Cheer, JF López-Giménez, JF López-Giménez, JJ Rodriguez, JM Franklin, JM Walker, JR Clapper, K Baba, K Mackie, K Monory, K Tsou, K Tsou, KA Gleason, L a. H Miner, L Callén, L Lanfumey, Laurence Lanfumey, Leonardo Pardo, Lesley A. Howell, LJ Sim-Selley, LP Martin, LTO Lee, M Bouvier, M Fribourg, M Lüttgen, M Schneider, M-M Mocanu, MJ Orejarena, N Kabli, NA Darmani, NB Eddy, NV Weisstaub, O Söderberg, P Pacher, P Rivera, Paola Gasperini, Patricia Robledo, Peter J. McCormick, R Franco, R Maldonado, R Mechoulam, R Mongeau, R Nygaard, R Schroder, Rafael de La Torre, Rafael Maldonado, RL Jakab, S Ferre, S Ferré, S Ferré, S González, S Haj-Dahmane, S Mato, S Pellow, SGF Rasmussen, SGF Rasmussen, SM Eggan, T Issad, T-W Chen, V Mendizábal, X Guitart, Xavier Viñals, Y-C Chiang   +112 more
core   +6 more sources

Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosing

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study was to develop a novel workflow to identify human urine biomarkers for drugs of abuse and new psychoactive substances. Metabolites of amphetamine, cocaine, LSD, MDMA, methamphetamine, THC, MDMB‐CHMICA, and MDPPP were first identified in a zebrafish embryo (ZE) metabolism study followed by comparison to most abundant human ...
Simon K. Wellenberg, Tanja M. Gampfer, Lea Wagmann, Philip Schippers, Jennifer Herrmann, Rolf Müller, Folker Westphal, Markus R. Meyer   +7 more
wiley   +1 more source

Population pharmacokinetic modelling revealed large variability in oromucosal absorption of Δ9‐tetrahydrocannabinol in older patients with poor appetite

British Journal of Clinical Pharmacology, EarlyView.
Aim Cannabis‐based medicines are gaining interest and being explored for new therapeutic indications, many of which commonly affect older medical patients. As most previous studies of the population pharmacokinetics of cannabinoids have been performed in healthy adults, this study aimed to investigate the population pharmacokinetics of Δ9 ...
Ida Klitzing Storgaard, Rikke Lundsgaard Nielsen, Morten Baltzer Houlind, Olivia Bornæs, Louise Westberg Strejby Christensen, Aino Leegaard Andersen, Helle Gybel Juul‐Larsen, Lillian Mørch Jørgensen, Torben Breindahl, Baker Nawfal Jawad, Izzet Altintas, Ove Andersen, Trine Meldgaard Lund   +12 more
wiley   +1 more source

Opioid and cannabinoid receptors

Current Opinion in Neurobiology, 1994
Opioids and cannabinoids are two major classes of drugs with important clinical uses as well as significant side effects. Recently, the three major subtypes of opioid receptors, delta, kappa and mu, have been cloned. Both the endogenous cannabinoids and their receptors have also recently been cloned.
T, Reisine, M J, Brownstein
openaire   +2 more sources

Development of indole sulfonamides as cannabinoid receptor negative allosteric modulators [PDF]

, 2016
This Letter was supported by the Biotechnology and Biological Sciences Research Council (BBSRC) and the Scottish Universities Life Sciences Alliance (SULSA) in 2011Peer ...
Abdelrahman, Mostafa Hamed, Baillie, Gemma L., Greig, Iain R., Ross, Ruth A., Trembleau, Laurent   +4 more
core   +1 more source

Low‐dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug–drug interaction study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Cannabidiol (CBD), the main non‐intoxicating compound from the cannabis plant, is regularly used by patients with chronic pain who also take analgesics. CBD has previously been shown to inhibit CYP‐mediated drug metabolism. This study aimed to characterize the potential pharmacokinetic interaction of CBD with amitriptyline and tramadol ...
Andriy A. Gorbenko, Titiaan E. Post, Pamela K. Strugala, Erica S. Klaassen, Linda E. Klumpers, Saco J. de Visser, Cristina Sempio, Jost Klawitter, Jules A. A. C. Heuberger, Geert J. Groeneveld   +9 more
wiley   +1 more source

Cannabinoid Receptor Activation Disrupts the Internal Structure of Hippocampal Sharp Wave–Ripple Complexes

Journal of Pharmacological Sciences, 2012
Cannabinoid agonists impair hippocampus-dependent learning and memory. Using mouse hippocampal slice preparations, we examined the effect of anandamide, an endogenous cannabinoid, on sharp wave–ripple (SW-R) complexes, which are believed to mediate ...
Yi Sun, Hiroaki Norimoto, Xiao-Ping Pu, Norio Matsuki, Yuji Ikegaya   +4 more
doaj   +1 more source